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Treatment Paradigms for Advanced Stage Non-small Cell
Lung Cancer in the Era of Multiple Lines of Therapy
Thomas E. Stinchcombe, MD, and Mark A. Socinski, MD
Abstract: The duration of first-line and the timing of second-line
therapy for advanced non-small cell lung cancer has been an area of
recent investigation. Five trials have been performed that have
investigated shorter (3–4 cycles) versus longer duration of platinum-
based therapy; four trials revealed an equivalent overall survival
with the shorter duration of therapy, and one trial revealed superior
survival with the longer duration of therapy. The toxicity and quality
of life data has either been equivalent or favored the shorter duration
of therapy. Two trials have investigated the timing of a second-line
therapy after completion of four cycles of platinum-based therapy
versus the standard treatment paradigm of initiating second-line
therapy upon disease progression. Both of these trials have revealed
a statistically significant improvement in the progression-free sur-
vival, and a trend towards improved survival for the earlier use of
second-line therapy. Only 50 to 60% of patients on the standard
treatment arm initiated second-line therapy, and the promising
results observed are most likely related to the fact that a higher
percentage of patients received second-line therapy on the experi-
mental arm. Several trials have investigated maintenance chemo-
therapy, and these trials have not revealed a survival benefit prob-
ably due to the fact that many patients experience disease
progression or unacceptable toxicity during the initial or mainte-
nance therapy. The addition of a targeted agent (bevacizumab or
cetuximab) to the initial chemotherapy and the continuation of the
targeted agent after completion of the chemotherapy have yielded
superior overall survival in comparison to chemotherapy alone. The
incremental benefit of the maintenance therapy with the targeted
agent is unknown.
Key Words: Non-small cell lung cancer, Chemotherapy, Mainte-
nance chemotherapy, Platinum-based chemotherapy.
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Lung cancer is the leading cause of cancer mortality in theUnited States and it is estimated that in 2008 more patients
will die of lung cancer than colon, breast, and prostate cancer
combined.1 Approximately 85% of the cases will be non-
small cell lung cancer (NSCLC), and 65% of patients will
have advanced stage disease at the time of diagnosis.2,3 For
patients with advanced stage NSCLC and a preserved func-
tional status the standard therapy is double agent platinum-
based therapy, although nonplatinum based doublets are ac-
ceptable alternative.4 Most patients who receive first-line
chemotherapy will experience disease progression within 3 to
6 months of initiating therapy and the median survival time
observed is 8 to 10 months.5,6 Second-line therapies (erlo-
tinib, pemetrexed, and docetaxel) improve survival and pal-
liate symptoms, but are typically administered at the time of
disease progression.7–10 Erlotinib is approved by the United
States Food and Drug Administration (FDA) in the second
and third-line setting. The development of effective therapies
after initial platinum therapy has raised questions about the
duration of first-line therapy, the optimal time to initiate
second-line therapy, and the treatment paradigm that is most
likely to insure patients receive the three lines of therapy.
Recently phase III trials have revealed an improvement in
overall survival (OS) with the addition of targeted agents
against vascular endothelial growth factor and the epidermal
growth factor receptor (EGFR) to platinum-based therapy in
comparison to chemotherapy alone.6,11 In both of these trials
the targeted agents were continued after the completion of
platinum-based therapy as “maintenance” therapy. It is un-
clear what the best method of integrating these targeted
therapies into our current standard treatment paradigms for
second-line therapy. The treatment paradigm that success-
fully delivers multiple lines of effective therapy or optimizes
the therapeutic benefit of all therapies will be the paradigm
that is most likely to improve survival.
Several trials have investigated a shorter versus a
longer course of platinum based therapy in the first-line
settting.12–16 Recently several trials have investigated the
timing of second-line chemotherapy after first-line platinum-
based therapy.17,18 In these trials patients randomized to the
experimental arm received treatment with an established
second-line agent immediately after the completion of first-
line therapy and patients randomized to the standard treat-
ment arm initiated second-line therapy at the time of disease
progression.
The variety of treatment strategies investigated in clin-
ical trials, the different agents investigated, and differing
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trials designs has created difficulty in determining the optimal
treatment strategy.
Further confusing the interpretation of the trials is that
a variety of terminology has been used to describe the
treatment strategies. This review will use the term duration of
therapy to describe trials that investigate a shorter versus
longer course of the same platinum-based chemotherapy
combination. Trials investigating the treatment strategy of
alternating or sequential combinations of therapy are of
interest, but are beyond the scope of this review. For purposes
of this review the term maintenance chemotherapy will apply
to trials that investigated the treatment strategy of initial
treatment with a platinum doublet for a set number of cycles
and continuation of the nonplatinum agent (i.e., initial ther-
apy with carboplatin and paclitaxel followed by continuation
of single agent paclitaxel) or the initiation of a different agent
that is currently not approved by the FDA in the second-line
setting. Trials that investigate the immediate initiation of a
second-line agent approved by the FDA versus observation
and initiation of therapy at the time of disease progression are
considered trials investigating the timing of second-line ther-
apy. We realize that these distinctions are arbitrary and
debatable and they are only intended to provide a structure
and clarity for this review.
Another factor making interpretation of these trials
difficult is that different primary end-points have been used,
and the preferred primary end-point for these trials is a matter
of debate. Both progression-free survival (PFS) and OS
end-points have advantages and disadvantages. The advan-
tages of the end-point of PFS include earlier assessment of
benefit in comparison to OS and the fact that PFS is not
confounded by the use of subsequent therapies. Disease
progression also often correlates with worsening of patients
symptoms and decline in quality of life (QoL). The potential
disadvantage of PFS is that a modest difference in PFS may
not correlate with improvement in QoL or result in improved
OS. The use of OS is perceived as more definitive; however,
there can be significant variability in the subsequent therapies
available, practice patterns, and therapies such as erlotinib
and gefitinib can have significant differences in efficacy
depending on the geographic region. Thus, in the current era
of multiple lines of therapy the end-point of OS may not be
as definitive as in the past. An assessment of QoL may
provide additional information to assist in the assessment of
the clinical benefit.
Duration of First-Line Platinum Therapy
Several phase III trials have investigated the duration of
first-line platinum-based therapy (Table 1). Four of these
trials have compared a defined course of therapy (three or
four cycles) versus a longer course of therapy (six cycles or
until disease progression) and patients were randomized to
one of the two treatment arms at the time of enroll-
ment.12,13,15,16 These trials have revealed equivalent survival,
and the QoL has either favored the shorter course therapy13,16
or been equivalent.12 The trial by Barata et al., compared four
versus six cycles of carboplatin and gemcitabine. The time to
tumor progression (TTP) was not significantly different be-
tween the four and six cycle treatment arms (4 and 5 months,
respectively; p  0.077), but the OS was significantly longer
on the six cycle treatment arm in comparison to the four cycle
treatment arm (p  0.047). The median survival time on the
four and six cycle treatment arms were 7 months (95%
confidence interval CI, 5.9–8.1 months) and 12 months
(95% CI, 9.8–14.2 months), respectively but there was no
difference in the 1-year survival rate. Approximately 14% of
patients on both treatment arms received second-line therapy.
The rate of grade 3 or 4 hematologic toxicities and all grades
of nausea and vomiting were similar between the two treat-
ment arms.
Park et al.14 investigated the duration of therapy but
used a different trial design; patients received two cycles of
cisplatin in combination with a taxane (paclitaxel or do-
cetaxel) or gemcitabine, and then patients who demonstrated
stable disease or a response after two cycles were randomized
to two or four additional cycles of therapy. The primary
end-point of the trial was overall survival, and the trial was
designed to demonstrate the noninferiority of four cycles,
TABLE 1. Select Phase III Trials Investigating the Duration of Platinum-Based Therapy
First Author Year Chemotherapy Treatment arms (n) Time to disease progression Median survival time
1-yr
Survival
Smith13 2001 MVP 3 cycles (155) 5 mo 6 mo 22%
6 cycles (153) 5 mo 7 mo 25%
Socinski12 2002 CP 4 cycles (114) NR 6.6 mo 28%
Continuation (116)a NR 8.5 mo 34%
Von Plessen16 2006 CV 3 cycles (150) 16 wk 28 wk 25%
6 cycles (147) 21 wk 32 wk 25%
Park14 2007 Cisplatin-based 4 cycles (156)b 4.6 moc 15.9 mo 59%
6 cycles (158) 6.2 mo 14.9 mo 62.4%
Barata15 2007 CG 4 cycles (110) 4 mo 7 moc NR
6 cycles (110) 5 mo 12 mo NR
a Patients continued therapy until disease progression or unacceptable toxicity.
b Patients who had stable disease or response after cisplatin in combination with paclitaxel, docetaxel or gemcitabine were randomized to two or four additional cycles of therapy.
Numbers reflect patients randomized.
c Statistically significant difference in the two treatment arms.
MVP, mitomycin, vinblastine, cisplatin; CP, carboplatin/paclitaxel; CG, carboplatin/gemcitabine; CV, carboplatin/vinorelbine; NR, not reported.
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using a noninferiority margin 15% for a 1-year survival rate
with an 80% power. A total of 452 were enrolled, and 314
(69.5%) were randomized. The median number of cycles
patients received on the 4 cycle and 6 cycle treatment arms
was 4 and 6, respectively. The 1-year survival rates observed
on the six-cycle and four-cycle treatment arms were 59% and
62.4%, respectively, and the difference of 3.4% (95% CI
8.0 to 4.8) met the predefined criteria for noninferiority.
The TTP on the six and four cycle treatment arms were 6.2
months (95% CI, 5.7–6.7) and 4.6 months (95% CI, 4.4–
4.8), respectively (p  0.001). The rates of hematologic and
nonhematologic toxicities were similar between the two treat-
ment arms, and there was no evidence of cumulative toxicity.
The percentage of patients receiving second-line therapy on
the six and four cycle treatment arms were 62.7% and 74.4%,
respectively, and the difference was statistically significant
(p  0.026). The QoL of the patients on the two treatment
arms was similar during the first 4 cycles, but from comple-
tion of four cycles to 3 months later patients on the four cycle
treatment arm experienced significantly less nausea/vomiting,
sore mouth, and dyspnea (0.05) compared with patients on
the six cycle treatment arm. Patients on the four cycle arm
also had a significant improvement in role-functioning com-
pared with patients on the six cycle treatment arm.
The data from four of the five trials support a duration
of platinum-based therapy for 3 to 4 cycles since longer
therapy has not yielded an improvement in OS or QoL. The
preliminary results of the trial by Barata et al., support the
continuation of therapy to six cycles since there was an
improvement in the median survival time and no increased
toxicity observed on this trial. The absolute improvement in
median survival time (5 months) observed is significant, and
is greater than the difference observed with the addition third
targeted agent to platinum-based therapy on recent phase III
trials.6,11 The patient characteristics and the rate of second-
line therapy are similar, thus it does not appear prognostic
factors and subsequent therapies contributed to the differ-
ence. The lack of a survival benefit observed on the trial by
Park et al., and the statistically significant lower percentage of
patients receiving second-line therapy on the six cycle treat-
ment arm is concerning given the fact that second-line ther-
apies have been proven to extend survival and improve QoL.
We feel the cumulative data support the use of a shorter
duration of first-line therapy.
Maintenance Chemotherapy
Trials investigating maintenance therapy (which for
this review has been defined as the continuation of one of the
initial agents or the initiation of new agent that is not
approved for use in the second-line setting by FDA) have not
revealed an improvement in OS (Table 2).19–21 One signifi-
cant challenge in assessing this treatment paradigm is that a
significant number of patients experience disease progression
or unacceptable toxicity during the initial therapy or during
the maintenance phase and do not receive the intended
therapy. On the trials by Westeel et al.21 Brodowicz et al.19
and Belani et al.20 all patients received platinum-based ther-
apy and only 32, 59%, and 32% of the patients, respectively,
underwent randomization to maintenance therapy or obser-
vation. In the trial by Westeel et al., only 23% of patients
completed the intended course of weekly vinorelbine for 6
months, and in the trial by Belani et al., only 23% of patients
completed the four full cycles of weekly paclitaxel.
In the trial by Brodowicz et al.19 patients received
initial therapy with cisplatin and gemcitabine, and were
randomized to single agent gemcitabine or observation, and
the median number of cycles of single agent gemcitabine
(days 1 and 8 every 21 days) was 3 (range 0–38). The
primary end-point was TTP throughout the whole study
period. The time tumor progression observed on the gemcit-
abine and observation arms throughout the study period was
6.6 and 5 months (p  0.001), respectively; the TTP after
randomization was 3.6 and 2.0, respectively (p 0.001). The
median OS times observed on the gemcitabine and observa-
tions arms throughout the study period were 13.0 and 11.0
months, respectively (p  0.195), and after randomization
were 10.2 and 8.1, respectively (p  0.172). The trial by
Belani et al., was not statistically powered to assess the
efficacy of the maintenance paclitaxel. The median TTP on
the paclitaxel and observation arms were 38 and 29 weeks,
respectively; and the median survival time was 75 weeks and
60 weeks, respectively. On the Westeel et al., trial the median
progression free survival times observed on the vinorelbine and
observation arms were 5 and 3 months (hazard ratio HR 
0.77; 95% CI, 0.56–1.07, p  0.11), and the median OS times
observed on both arms was 12.3 months (HR  1.08; 95% CI,
0.79–1.47, p  0.65).
TABLE 2. Select Phase III Trials of Maintenance Chemotherapy
First
Author Year Chemotherapy (n)a Median Progression-Free Survival Median Overall Survival Time
Westeel21 2005 Vinorelbine (91) 5 mob 12.3 mob
Observation (90) 3 mo 12.3 mo
Belani20 2003 Paclitaxel (65) 38 wk 75 wk
Observation (65) 29 wk 60 wk
Brodowicz19 2006 Gemcitabine (138) 3.6c mo 10.2 mo
Observation (68) 2.0 mo 8.1 mo
a N-values represent number of patients randomized.
b The hazard ratio of progression-free survival was 0.77 (95% CI, 0.56–1.07; p  0.65), and the hazard ratio for overall survival was 1.08 (95% CI, 0.79–1.47; p  0.65).
c Data reported as time after randomization and for time to tumor progression p value 0.001, and for overall survival p value  0.172.
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This data has raised questions about the feasibility and
benefits of this approach, and it has not been widely imple-
mented. However, the difference in TTP observed and a trend
towards an improvement in OS did initiate an interest in
developing other trials with other agents and trial designs
where patients were randomized to further therapy or obser-
vation after completion of the initial therapy.
Timing of Second-Line Therapy
The current standard treatment paradigm is to treat
patients for a defined number of cycles of first-line chemo-
therapy and observe the patient for symptomatic or radio-
graphic evidence of disease progression.4 At the time of
disease progression patients in the United States are generally
initiated on second-line therapy with one of the three agents
(doectaxel, pemetrexed, and erlotinib), and in some countries
gefitinib is available. The standard method of monitoring for
disease progression has not been established, and undoubt-
edly there is variability in the frequency of clinic visits and
radiologic testing of patients. The rate of patients receiving
second-line therapy on recent phase III first-line trials is 50 to
60%.6,11,22 Recently there have been two phase III trials that
have investigated the timing of initiating second-line therapy.
On both of these trials patients received four cycles of initial
platinum-based therapy and were randomized to the standard
treatment paradigm or the experimental paradigm of initiating
second-line therapy immediately after completion of plati-
num-based therapy.
On the trial by Fidias et al.17 patients received four
cycles of carboplatin and gemcitabine and patients experienc-
ing a response or stable disease were randomized to imme-
diate docetaxel versus the initiation of docetaxel at the time of
disease progression (Table 3). On both treatment arms pa-
tients received docetaxel until disease progression, unaccept-
able toxicity, or a maximum of six cycles. Patients on the
immediate docetaxel arm were seen every 3 weeks and
underwent scans after every two cycles (6 weeks), and then
after completion of six cycles therapy had follow-up visits
every 3 weeks. Patients on the standard arm were seen by a
physician every 3 weeks and underwent repeat imaging every
3 months or if clinically indicated by the treating physician.
The primary end-point was OS from the date of randomiza-
tion, and preliminary results are available. A total of 552
patients were enrolled, 307 patients experienced stable dis-
ease or a response; 153 patients were randomized to imme-
diate docetaxel and 142 (93%) received treatment, and 154
patients were randomized to delayed docetaxel and 91 (59%)
received treatment. The median OS of the randomized pop-
ulation on the immediate and delayed docetaxel arms were
not significantly different (11.9 and 9.1 months, respectively,
p  0.071). The median PFS of the randomized patient
population on the immediate and delayed docetaxel arms was
significantly longer than the delayed arm (p   0.0001).
There was no significant difference in the QoL between the
two treatment arms. Of the patients on the delayed docetaxel
arm who did not receive therapy (n 63) the main reasons on
preliminary review were: disease progression (n  25),
unknown or missing (n  12), patient decision (n  10),
death (n  4), investigator decision to change therapy (n 
3), and withdrew consent (n  2).
The preliminary data from the trial by Fidias et al.17
reveals a promising trend towards an improvement in OS, and
a particular strength of this trial is that the second-line therapy
was the same in both treatment arms. Thus, this trial design
eliminates variability in the type of agents used in the second-
line therapy, and the use of agents that are not approved by
the FDA in the second-line setting. One interesting compar-
ison will be the OS of patients who received docetaxel on the
immediate docetaxel arm and on the delayed docetaxel arm.
If the OS is similar for patients receiving docetaxel on both
treatment arms it would be suggestive that the difference in
OS observed on the randomized population was related to a
difference in the rate of delivery of second-line therapy.
A trial by Ciuleanu et al.18 randomized patients after
four cycles of a platinum-doublet to either pemetrexed or
placebo every 3 weeks.18 Patients on both arms were seen by
a physician every cycle, and underwent radiologic imaging
every two cycles (6 weeks). On the placebo arm the choice of
second-line therapy upon disease progression was at the
discretion of the physician, and 11% of patients received
pemetrexed as second-line therapy. The primary end-point
was PFS from the time of randomization. The median number
of cycles of therapy on the pemetrexed and placebo arms
were 4 (range 1–34) and 3 (range 1–30), respectively. This
trial revealed a statistically significant improvement in the
PFS with the immediate initiation of pemetrexed, and pre-
liminary OS results revealed a statistically nonsignificant
difference in OS with 55% of the patients censored (Table 3).
When subsequent therapies were analyzed 37.2% of patients
on the pemetrexed and 50% of patients on the placebo arm
received subsequent systemic therapies (p  0.008). The
types of subsequent therapies patients received were balanced
between the two treatment arms.
In a subset analysis there was a statistically significant
difference in OS in patients with nonsquamous histology
(n  482). A median survival of 14.4 months was observed
in patients nonsquamous histology who initiated immediate
pemetrexed in comparison to 9.4 months for patients who
were on the observation arm (p  0.005). The PFS for
patients who immediately received pemetrexed and on the
observation arm were 4.37 and 1.84 months, respectively
(p  0.00001). In the patients with squamous histology (n 
181) a median survival of 9.6 months was observed in
patients who immediately initiated pemetrexed in comparison
to 11.9 months for patients on the observation arm (p 
0.231) The PFS on the immediate pemetrexed and observa-
tion arms were 2.43 and 2.50, respectively (p  0.896).
Retrospective data from a phase III second-line trial compar-
ing docetaxel verses pemetrexed, and a prospective subset
analysis of cisplatin/pemetrexed versus cisplatin/gemcitabine
in the first-line setting have demonstrated a similar interaction
between histology and efficacy of pemetrexed.22,23 The cu-
mulative data from these analyses indicates that the efficacy
of pemetrexed in patients with squamous histology is limited,
and pemetrexed should only be used in patients with
nonsquamous histology.
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These two trials reveal a flaw with the current treatment
paradigm of monitoring patients and initiating therapy at the
time for disease progression. With this approach 40 to 50% of
patients on the trials by Fidias et al., and Ciuleanu et al., never
initiated second-line therapy. The rate of patients not receiv-
ing second-line therapy is similar to the rate observed on
recent phase III first-line trials of first-line therapy.6,11,22
There are multiple reasons for the rate of second-line chemo-
therapy delivery observed on these trials. Many patients may
not be appropriate candidates for second-line therapy due to
decline in performance status, intercurrent illnesses, and
some patients may elected not to initiate second-line therapy.
However, a certain percentage of patients experience rapid
disease progression after completion of first-line therapy and
are consequently not candidates for second-line therapy. This
patient population may benefit from the immediate initiation
of second-line therapy provided they are able to tolerate and
experience stable disease or a response to the therapy. There
is also a patient population that will experience a durable
response or stable disease after first-line therapy, and this
patient population may not benefit from the immediate initi-
ation of second-line therapy. Thus, the heterogeneity and
unpredictability of NSCLC make it difficult to anticipate the
optimal time to initiate and to select the patient population
who will benefit from the immediate initiation of second-line
therapy.
On both of these trials the patients were seen by a
physician every 3 weeks and assessed for symptomatic pro-
gression, and the interval of radiologic assessment for disease
progression was every 6 weeks on both arms on the trial by
Ciuleanu et al., or every twelve weeks on the delayed do-
cetaxel arm on the trial by Fidias et al., The median progres-
sion-free period after randomization on the placebo arms
observed on the trials by Fidias et al., and Ciuleanu et al.,
were 2.8 and 1.97 months, respectively. Thus, on the both
trials a significant percentage of patients had symptomatic
progression soon after completion of the initial platinum
therapy, and even with the every 6 week imaging on the trial
by Ciuleanu only 50% of patients on the placebo arm re-
ceived second-line therapy. Thus, it does not appear more
frequent clinic visits or radiologic imaging will be sufficient
to detect progression before it adversely impacts the patients’
ability to receive second-line therapy.
The proper selection of patients will be critical to the
future development of this treatment paradigm, and even
under the best of circumstances not all patients will be
candidates or benefit from the early initiation of second-line
therapy. Patients with a good baseline performance status,
female gender, and nonsquamous histology are more likely to
receive second-line therapy.24 In previous analyses of second-
line therapy the best response to first-line therapy, perfor-
mance status, gender, and stage at diagnosis have been found
to prognostic.25,26 The time since completion or time from
initiation of first-line chemotherapy has been found to be
prognostic as well.10,25 A combination of clinical and molec-
ular factors yet to be clearly defined may allow the selection
of the patients most-likely to benefit from the immediate
initiation of second-line therapy. The use of pemetrexed with
this strategy should be restricted to patients with nonsqua-
mous histology.
Meta-Analysis
To evaluate the effect of duration of chemotherapy
recently a meta-analysis27 was performed on this subject
which included 13 trials12–17,19–21,28–31The meta-analysis per-
formed for the end-point PFS (n  1907) revealed an im-
provement in PFS with extending chemotherapy duration,
and if a subset analysis was performed the improvement in
PFS was statistically significant with third generation thera-
pies (n  1524) but not with therapies that did not contain a
third generation agent (n  382). When the meta-analysis is
performed for the end-point of OS (n  2416) the extension
of chemotherapy did not have an effect on OS, and there was
no improvement in OS with third generation agents. The lack
of improvement in OS was still present with the meta-
analysis was performed using the 10 best quality trials (n 
2267). If the meta-analysis is repeated for the end-point of OS
including the preliminary survival results from the trial by
Ciuleanu et al., (n 3079) then the meta-analysis does reveal
an improvement in OS (HR  0.92, 95% CI 0.86–0.99; p 
0.03). In our opinion, this meta-analysis does not support
extending the duration of therapy at this time since the
TABLE 3. Select Trials of Immediate Second-line vs Delayed Second-Line Therapy
First Author Year
No. of
Patients
Randomized
No. of
Patients
Treated Treatment
Median PFS
(95% CI) (mo) p
OS Median
(95% CI) (mo) p
Fidias17 2007 307 142 Immediate 6.5 (4.4–7.2) 0.0001 11.9 (10–13.7) 0.071
91 Delayed 2.8 (2.6–3.4) 9.1 (8.0–11.2)
Cinleanu18 2008 663 432 Pemetrexed 4.04 (3.06–4.44)a 0.00001 13.01 (11.40–14.42) 0.060a
221 Placebo 1.97 (1.54–2.76) 10.18 (8.57–13.17)
Nonsquamous 482 NR Pemetrexed 4.37 0.00001 14.4 0.005
Subset NR Placebo 1.84 9.4
Squamous 181 NR Pemetrexed 2.43 0.896 9.6 0.231
Subset NR Placebo 2.50 11.9
a Progression-Free Survival hazard ratio (HR)  0.599 (95% CI: 0.49–0.73); p value 0.0001; Overall Survival HR  0.798 (95% CI: 0.63–1.01) p value  0.060.
PFS, Progression-free survival; OS, overall survival; NR, not reported; CI, confidence interval.
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survival results from the trial by Ciuleanu et al., are not
mature. It also may not take into account the differential
effect that effective second-line therapies have on survival.
Gefitinib
A trial by the West Japan Thoracic Oncology Group
investigated the role of gefitinib after platinum-based therapy
(Table 4).32 Patients enrolled on this trial were randomized to
3 cycles of platinum-based therapy or three cycles of
platinum-based therapy followed gefitinib, and the primary
end-point was OS. The median number of chemotherapy
cycles on both arms was three, and on the chemotherapy
followed by gefitinib 172 (57%) patients initiated gefitinib.
On poststudy therapy approximately 35% of patients received
docetaxel on both arms, and on the chemotherapy alone arm
51.3% received gefitinib and on the chemotherapy followed
by gefitinib arm 28.6% continued to receive gefitinib. There
was a significant improvement in PFS, but no significant
difference in OS (Table 4). On a subset analysis of patients
with adenocarcinoma histology (n  467) a significant im-
provement in OS with chemotherapy followed by gefitinib
was observed. When a subset analysis was performed on
smoking status the patients with a history of never smoking
(n  185) had a similar survival with both treatments, but
76% of patients assigned to the chemotherapy alone arm
subsequently received gefitinib. This trial included a large
number of patients with a higher prevalence of activating
epidermal growth factor mutations (EGFR) (31% of patients
were never smokers, 100% were Asian, 78% had adenocar-
cinoma histology) and the applicability of this treatment
paradigm in patient populations with a lower rate of activat-
ing EGFR mutations is yet to be determined. The fact that
patients on both treatment arms received a median of three
cycles of chemotherapy and 50% of the patients on chemo-
therapy alone subsequently received gefitinib makes interpre-
tation of the initial therapy’s impact on survival challenging.
Maintenance Therapy with Targeted Agents
Two phase III trials that have investigated platinum-
based therapy with or without bevacizumab or cetuximab
have revealed an improvement in OS.6,11 A second phase III
trial with bevacizumab revealed an improvement in PFS but
not in OS33 and a second phase III trial with cetuximab did
not reveal an improvement in PFS or OS.34 All four of these
trials continued the targeted agent after completion of the
combination of chemotherapy and the targeted therapy. The
hypothesis is that the continuation of the targeted agent would
delay disease progression and improve overall survival, and
the treatment with the targeted agent alone would be well
tolerated. Eastern Cooperative Oncology Group trial 4599
revealed an improvement in OS with the addition of bevaci-
zumab to carboplatin and paclitaxel.6 Of the 407 patients
who received carboplatin, paclitaxel and bevacizumab 215
(53%) received bevacizumab monotherapy and of these
107 (50%) received greater than five cycles of therapy. On
the phase III trial of cisplatin and vinorelbine with and
without cetuximab (the FLEX trial) 241 of 548 patients did
not experience progressive disease or unacceptable toxic-
ity and were eligible for maintenance therapy, and 80% of
the eligible patients received cetuximab.11 The median
duration of therapy was 18 weeks. The data from these
trials indicate this approach is feasible, but they do not
provide data about the incremental benefit of continuing
the targeted agent beyond completion of the initial treat-
ment with combination of the targeted agent and chemo-
therapy. The single agent activity of bevacizumab and
cetuximab in NSCLC appears to be modest,35,36 and con-
cerns about acute and potential cumulative toxicities as
well as the economic costs have raised questions about this
practice. To accurately assess the risks and benefits of
maintenance therapy with bevacizumab or cetuximab a
well designed phase III trial investigating this clinical
question would be required. Currently our practice when
TABLE 4. Results of West Japan Thoracic Oncology Trial (WJTOG 0203)
First Author Year Treatment (n) Median PFS (mo) HR Median OS (mo) HR
Hida32 2008 Chemotherapy alone (298) 4.27 0.68 (95% CI 0.57–0.80)
p value0.001
12.89 0.86 (96% CI 0.72–1.03)
p  0.10
Chemotherapy3 Gefitinib
(300)
4.60 13.68
Overall survival
Subset analysis Treatment Median OS p
Adenocarcinoma
(n  467)
Nonadenocarcinoma
(n  128)
Never-smoker
(n  185)
Smoker
(n  410)
Chemotherapy alone
Chemotherapy3 Gefitinib
Chemotherapy alone
Chemotherapy3 Gefitinib
Chemotherapy alone
Chemotherapy3 Gefitinib
Chemotherapy alone
Chemotherapy3 Gefitinib
14.33
15.42
9.17
7.69
23.51
21.65
10.03
11.67
p  0.03
p  0.24
p  0.72
p  0.03
PFS, progression-free survival; HR, hazard ratio; OS, overall survival; NR, not reported; CI, confidence interval.
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incorporating bevacizumab into the first-line therapy has
been to continue the bevacizumab until disease progres-
sion or unacceptable toxicity based on the treatment par-
adigm used in ECOG 4599. If cetuximab receives approval
by the FDA for NSCLC we will continue single agent
cetuximab after completion of chemotherapy based on the
treatment paradigm used in the FLEX trial.
CONCLUSIONS
We believe the standard initial duration of platinum-based
therapy should be three to four cycles since four of the five trial
investigating the duration of platinum therapy in the first-line
setting have revealed equivalent survival with the shorter dura-
tion of therapy.37 The immediate initiation of agents with proven
activity in the second-line after completion of four cycles plat-
inum-based therapy appears to be the most promising treatment
strategy due to the fact that a higher percentage of patients
received second-line therapy in comparison to our current treat-
ment paradigm. These two trials also illustrate that the proper
selection of the end-point for trials is problematic and has yet to
be determined. For instance, the trial by Fidias et al., employed
the primary end-point of OS and is considered a “negative” trial
while the trial by Ciuleanu et al., used the primary end-point of
PFS and is considered a “positive” trial despite a similar absolute
improvement in PFS and OS observed in the two trials. Even if
the paradigm of immediate initiation of second-line agents is
implemented a significant percentage of patients will not be
candidates for further treatment and will not benefit from this
treatment paradigm. The proper selection of patients will most
likely depend on clinical factors including histology and smok-
ing history, molecular factors such as the presence or absence of
activating EGFRmutations, the toxicity the patients experienced
during the initial therapy, and physician and patient preferences.
Inevitably clinicians will be required to make an individual
assessment of the data and whether it applies to an individual
patient and discuss the potential advantages and disadvantages
of a treatment strategy with the patient.
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